Document Detail


Pharmacotherapy for treatment-refractory schizophrenia.
MedLine Citation:
PMID:  21254948     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a large percentage of persons with schizophrenia remain at least partially nonresponsive to treatment, leading to increased morbidity/mortality, increased healthcare cost, and poor quality of life for affected individuals. AREAS COVERED: this paper comprises a review of recent research in drug therapy for schizophrenia, particularly treatment-refractory schizophrenia, with a focus on research conducted between 2005 and June 2010. Databases that were searched include: Pubmed, CINAHL, Science Direct, Medline and Clinical Trials.gov. Primary search terms were 'treatment-refractory schizophrenia' and 'treatment-resistant schizophrenia', with cross reference to specific agents covered in this article. An objective perspective on current trends in pharmacotherapy for treatment-refractory schizophrenia. We review the available evidence and discuss the strengths and weaknesses of published data in this field. EXPERT OPINION: although there have been many advances in pharmacotherapy for schizophrenia, more well-designed trials are required to establish true efficacy and safety of current prescribing trends in clinical practice.
Authors:
Scott P Van Sant; Peter F Buckley
Related Documents :
8154598 - Direct-reading instruments for aerosols. a review.
23317388 - Aphasia and topic initiation in conversation: a case study.
21162058 - Looking to the future of research in pediatric anxiety disorders.
19282058 - The power of vivid experience in hand hygiene compliance.
22834078 - Intracellular nucleic acid interactions facilitated by quantum dots: conceptualizing th...
18351158 - The designing of anti-diphtheria serotherapy at the institut pasteur (1888-1900): the r...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  12     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-24     Completed Date:  2011-04-20     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  411-34     Citation Subset:  IM    
Affiliation:
Medical College of Georgia, Department of Psychiatry and Health Behavior, Augusta, GA 30912, USA. svansant@mcg.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antipsychotic Agents / therapeutic use*
Clozapine / therapeutic use
Drug Resistance
Electroconvulsive Therapy / methods
Health Care Costs
Humans
Quality of Life*
Schizophrenia / drug therapy*,  physiopathology,  therapy
Transcranial Magnetic Stimulation / methods
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 5786-21-0/Clozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacotherapy for squamous-cell carcinoma of the head and neck.
Next Document:  Ivabradine: recent and potential applications in clinical practice.